Slide 1: GNI Group Ltd. Q4 FY2020 Financial Results
GNI Group Ltd. Q4 FY2020 Financial Results Corporate Presentation February 16, 2021 We Bring New Hope to Patients Securities Code: 2160
Slide 2: Forward-looking Statements
We Bring New Hope to Patients Forward-looking Statements This presentation contains statements concerning the current plans, expectations and strategies of GNI Group Ltd. (GNI Group). Any statements contained herein that pertain to future operating performance and that are not historic facts are for
Slide 3: FY2020 – Q4 Highlights
We Bring New Hope to Patients FY2020 – Q4 Highlights Strong revenue growth defying global pandemic Strong sales growth of Etuary reflects the demand of our drug even during COVID reduced hospital visits by patients. BAB sales and profits in US testified that our products have good reputation and dem
Slide 4: Development: Pipeline Update
We Bring New Hope to Patients Development : Pipeline Update Product - Indication Origin Phase I Phase II Phase III Latest Status Etuary® (China) - Connective Tissue Disease Associated Dual Phase III clinical trials ongoing. Proceeding smoothly despite the Proprietary Interstitial Lung Disease (CTD-I
Slide 5: F351 – The 2nd Milestone in History
We Bring New Hope to Patients F351 – The 2nd Milestone in History ⚫ Submitted official communication request to CDE of NMPA. 1. How to proceed onto Phase 3 trial with or without early conditional approval. 2. How to expand to other important organ fibrosis 3. All decisions are up to CDE. ⚫ Preparing
Slide 6: Beijing Continent IPO Path
We Bring New Hope to Patients Beijing Continent IPO Path • Listing of subsidiaries (*start to hint at listing Cullgen/BAB) at major markets • Make the value of our long time investment obvious to GNI shareholders • Build up reputations their products • Recruiting top talents to strengthen management
Slide 7: Continued Investment into Cullgen
We Bring New Hope to Patients Continued Investment into Cullgen Cullgen is a leader in revolutionary protein degradation (Protac) field • Pipeline focus on oncology and other diseass • Multiple INDs will be filed in the next 6-18 months • >20 patents (PCTs) filed for first-in-class lead compounds •
Slide 8: Acquisition of Remaining Shares of BAB
We Bring New Hope to Patients Acquistion of Remaining Shares of BAB • BAB biomaterial products have much longer life than patent on drugs • Manufacture of high quality products take years to train staff (~30 in US) • Potentials of international markets have not been materialized yet • New product de
Slide 9: Contact Information
We Bring New Hope to Patients Contact Information infojapan@gnipharma.com © 2020 GNI Group Ltd. All rights reserved 9